公开(公告)号：US20240368551A1

公开(公告)日：2024-11-07

申请号：US18653210

申请日：2024-05-02

Applicant: SINAI HEALTH SYSTEM

Inventor： Adele CHANGOOR ,  Sarah Linda ALOI ,  Marc Daniel GRYNPAS

IPC: C12N5/077

Abstract: The specification provides an improved media formulation to enhance the viability of chondrocytes in stored biological samples. The formulation includes Dulbecco's Modified Eagle Medium (DMEM), doxycycline, and hyaluronic acid, in concentrations sufficient to maintain the chondrocytes' viability significantly longer than DMEM alone. This formulation allows biological samples containing chondrocytes to retain high viability rates for extended periods to be suitable for transplant purposes, such as in osteochondral tissue transplantation.

公开(公告)号：US20240092763A1

公开(公告)日：2024-03-21

申请号：US18271103

申请日：2022-01-07

Applicant: Ontario Institute for Cancer Research (OICR) ,  The Governing Council of The University of Toronto ,  Sinai Health System

Inventor： Rima Al-Awar ,  Liliana Attisano ,  Methvin Isaac ,  Yong Liu ,  David Smil ,  David Uehling ,  Jeff Wrana

IPC: C07D403/14 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08

CPC classification number: C07D403/14 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08

Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting or blocking NUAK kinase, such as cancers and fibrosis.

公开(公告)号：US20230414677A1

公开(公告)日：2023-12-28

申请号：US18175409

申请日：2023-02-27

Applicant: Sinai Health System

Inventor： Andras Nagy ,  Jeffrey Harding ,  Kristina Nagy

IPC: A61K35/545 ,  A61P27/02 ,  A61P7/04 ,  A61P9/10 ,  A61P1/16 ,  A61P3/00 ,  A61P37/06 ,  A61P19/02 ,  A61P3/10 ,  A61P25/16 ,  A61K45/06 ,  C07K14/47 ,  C07K14/52 ,  C07K14/705 ,  C12N5/0735 ,  C12N15/09

CPC classification number: A61K35/545 ,  A61P27/02 ,  A61P7/04 ,  A61P9/10 ,  A61P1/16 ,  A61P3/00 ,  A61P37/06 ,  A61P19/02 ,  A61P3/10 ,  A61P25/16 ,  A61K45/06 ,  C07K14/47 ,  C07K14/521 ,  C07K14/70503 ,  C07K14/70532 ,  C07K14/70575 ,  C12N5/0606 ,  C12N15/09 ,  C12N2510/00

Abstract: A cell genetically modified to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host is, and methods for making and using the same is provided. The cell comprises a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting, and whose function is one or more of: to mitigate antigen presenting cell activation and function; to mitigate graft attacking leukocyte activity or cytolytic function; to mitigate macrophage cytolytic function and phagocytosis of allograft cells; to induce apoptosis in graft attacking leukocytes; to mitigate local inflammatory proteins; and to protect against leukocyte-mediated apoptosis.

公开(公告)号：US20210161971A1

公开(公告)日：2021-06-03

申请号：US16621490

申请日：2018-06-12

Applicant: Sinai Health System

Inventor： Andras NAGY ,  Jeffrey HARDING ,  Kristina NAGY

IPC: A61K35/545 ,  C12N5/0735 ,  A61K45/06 ,  C07K14/705 ,  C07K14/52 ,  C07K14/47 ,  A61P37/06 ,  A61P27/02 ,  A61P25/16 ,  A61P9/10 ,  A61P19/02 ,  A61P3/10 ,  A61P7/04 ,  A61P3/00 ,  A61P1/16

Abstract: A cell genetically modified to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host, and methods for making and using the same are provided. The cell comprises a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting, and whose function is one or more of: to mitigate antigen presenting cell activation and function; to mitigate graft attacking leukocyte activity or cytolytic function; to mitigate macrophage cytolytic function and phagocytosis of allograft cells; to induce apoptosis in graft attacking leukocytes; to mitigate local inflammatory proteins; and to protect against leukocyte-mediated apoptosis. The transgenes comprise two or more of the following genes: PD-L 1, HLAG or H2-M3, Cd47, Cd200, FASLG or Fasl, Ccl21 or Ccl21b, Mfge8, and Serpin B9 or Spi6.

公开(公告)号：US20200016594A1

公开(公告)日：2020-01-16

申请号：US16338306

申请日：2017-09-29

Applicant: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO ,  SINAI HEALTH SYSTEM

Inventor： Aaron Ray WHEELER ,  Michael Dean CHAMBERLAIN ,  Julian Lucas LAMANNA ,  Michael David Murdoch DRYDEN ,  Elena KOLOMIETZ ,  David CHITAYAT

IPC: B01L3/00 ,  C12N1/06 ,  C12Q1/6806 ,  G01N1/28 ,  G01N15/14

Abstract: The present disclosure provides a system and method for identifying and targeting individual cells within a cell population for selective extraction of cellular content and a digital microfluidic device having at least one hydrophilic site for receiving cells, an imaging system including a stage for receiving the digital microfluidic device and an imaging module for identifying at least one targeted cell among the cells at the at least one hydrophilic site. The system includes a pulsed laser source for laser lysing the targeted cell thereby releasing the cell content to produce a lysate. A control system controls the pulsed laser source, the imaging system and the digital microfluidic device and is programmed for coordinating steps of i) movement of droplets on the digital microfluidic device, ii) selection of the at least one targeted cell to be lysed located at the at least one hydrophilic site, iii) illumination of the at least one selected targeted cell by the pulsed laser source to lyse the at least one selected targeted cell to produce lysate, and iv) collection of the lysate.

公开(公告)号：US10195044B2

公开(公告)日：2019-02-05

申请号：US14903622

申请日：2014-07-11

Applicant: Sinai Health System

Inventor： Rita Kandel ,  J. Paul Santerre ,  Shu Qiu Li

IPC: A61F2/44 ,  C12N5/00 ,  A61L27/18 ,  A61L27/36 ,  A61L27/38 ,  A61L27/12

Abstract: The disclosure relates to an intervertebral disc implant comprising a first construct comprising a continuous layer of nucleus pulposus (NP) tissue directly or indirectly on and integrated with a substrate, and a second construct surrounding the first construct comprising one or more continuous layers of annulus fibrosus (AF) tissue on and adherent to a scaffold, wherein the AF tissue, which is composed of single or multiple adherent layers, is integrated with the NP tissue. The disclosure also relates to methods of preparing the multi-tissue intervertebral disc and using the intervertebral disc as an implant.

公开(公告)号：US20170342495A1

公开(公告)日：2017-11-30

申请号：US15591185

申请日：2017-05-10

Applicant: Sinai Health System

Inventor： Jan Heng ,  Stephen Lye ,  Craig Pennell

IPC: C12Q1/68 ,  G01N33/68

CPC classification number: C12Q1/6883 ,  C12Q2600/158 ,  G01N33/689 ,  G01N2800/368

Abstract: The invention relates to novel markers of preterm birth, methods for assessing the status of preterm birth using the markers, and methods for the diagnosis and therapy of preterm birth.

公开(公告)号：US09775859B2

公开(公告)日：2017-10-03

申请号：US14158221

申请日：2014-01-17

Applicant: Sinai Health System ,  The Regents of the University of California

Inventor： Michael Demetriou ,  James Dennis ,  Ken Siu-Kwong Lau

IPC: A61K31/00 ,  A61K31/7072 ,  A01K67/027 ,  A61K31/593 ,  A61K31/70 ,  A61K45/06 ,  G01N33/564 ,  A61K31/7008

CPC classification number: A61K31/7072 ,  A01K67/0275 ,  A01K2227/105 ,  A01K2267/0318 ,  A61K31/593 ,  A61K31/70 ,  A61K31/7008 ,  A61K45/06 ,  G01N33/564 ,  G01N2400/10 ,  G01N2800/285 ,  A61K2300/00

Abstract: Contemplated compositions and methods are directed to prevent and/or treat various autoimmune diseases that are typically associated with glycan dysregulation, and especially autoimmune demyelinating diseases. Further especially contemplated aspects include animal models and systems for screening compounds to treat and/or prevent such diseases.

公开(公告)号：US20170138963A1

公开(公告)日：2017-05-18

申请号：US15360240

申请日：2016-11-23

Applicant: Sinai Health System

Inventor： Keith Jarvi ,  Eleftherios P. Diamandis ,  Andrei Drabovich

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/68 ,  G01N33/689 ,  G01N2333/705 ,  G01N2333/78 ,  G01N2800/34 ,  G01N2800/342 ,  G01N2800/367

Abstract: Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides, encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers.

公开(公告)号：US12031184B2

公开(公告)日：2024-07-09

申请号：US16630299

申请日：2018-07-11

Applicant: UNIVERSITY HEALTH NETWORK ,  SINAI HEALTH SYSTEM

Inventor： Daniel Diniz De Carvalho ,  Scott Victor Bratman ,  Rajat Singhania ,  Ankur Ravinarayana Chakravarthy ,  Shu Yi Shen

IPC: C12Q1/6886 ,  C12Q1/6827 ,  G16B5/20 ,  G16B40/00 ,  G16B30/20

CPC classification number: C12Q1/6886 ,  C12Q1/6827 ,  G16B5/20 ,  G16B40/00 ,  C12Q2522/10 ,  C12Q2537/164 ,  C12Q2600/154 ,  G16B30/20

Abstract: There is described herein a method of detecting the presence of DNA from cancer cells in a subject comprising: providing a sample of cell-free DNA from a subject; subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated, then optionally denaturing the sample; capturing cell-free methylated DNA using a binder selective for methylated polynucleotides; sequencing the captured cell-free methylated DNA; comparing the sequences of the captured cell-free methylated DNA to control cell-free methylated DNAs sequences from healthy and cancerous individuals and from individuals with distinct cancer types and subtypes; identifying the presence of DNA from cancer cells if there is a statistically significant similarity between one or more sequences of the captured cell-free methylated DNA and cell-free methylated DNAs sequences from cancerous individuals.